Sarepta Therapeutics, Inc. $SRPT Stock: Privium Fund Management B.V. Grows Position

Privium Fund Management B.V. raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 166,605 shares of the biotechnology company’s stock after purchasing an additional 30,105 shares during the period. Privium Fund Management B.V.’s holdings in Sarepta Therapeutics were worth $3,036,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Meeder Asset Management Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $27,000. Pinnacle Wealth Planning Services Inc. raised its position in Sarepta Therapeutics by 50.6% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 598 shares during the last quarter. Nykredit A S acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth $43,000. Ancora Advisors LLC purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $45,000. Finally, Allworth Financial LP purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $58,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded up $0.25 during mid-day trading on Friday, hitting $17.82. The stock had a trading volume of 2,596,194 shares, compared to its average volume of 2,726,443. The firm has a market cap of $1.88 billion, a PE ratio of -13.01, a PEG ratio of 0.33 and a beta of 0.45. The company’s 50-day simple moving average is $19.13 and its 200-day simple moving average is $18.64. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. Sarepta Therapeutics, Inc. has a fifty-two week low of $14.68 and a fifty-two week high of $24.68.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.06. The business had revenue of $381.35 million for the quarter, compared to analyst estimates of $352.20 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business’s revenue was down 4.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.13) earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.27 earnings per share for the current year.

Sarepta Therapeutics News Summary

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
• Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
• Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
• Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SRPT. Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 28th. HC Wainwright reiterated a “sell” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 5th. Benchmark restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, September 28th. Finally, William Blair raised Sarepta Therapeutics to a “hold” rating in a research note on Wednesday, September 23rd. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and seven have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $23.40.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.